Lawsuit Filed on Behalf of Limestone County in Response to Opioid Epidemic
Beasley Allen has filed its fourth lawsuit against opioid manufacturers and distributors on behalf of an Alabama city or county government. The complaint, filed on behalf of Limestone County, Alabama, alleges the marketing of these drugs contributed to the creation of the opioid epidemic, a public health and safety crisis.
In December, Beasley Allen filed two similar lawsuits on behalf of the City of Greenville, Alabama and Houston County, Alabama. In February, Beasley Allen filed additional lawsuits on behalf of Barbour County, Alabama, and Sumner County, Tennessee. The firm also is representing the State of Alabama in its opioid lawsuit against Purdue Pharmaceuticals.
Economic damages resulting from the opioid epidemic include costs for providing medical care, therapeutic care and treatments for patients suffering from opioid-related addiction or disease, including overdoses and deaths; costs for providing counseling and rehabilitation services; costs for treating infants born with opioid-related medical conditions; public safety and law enforcement expenses; and care for children whose parents suffer from opioid-related disability or incapacitation.
Four Alabama cities rank in the Top 15 in the nation with the highest rates of opioid abuse – Anniston, Gadsden, Montgomery and Tuscaloosa. Nationally, opioids are responsible for killing more than 183,000 people since 1999, according to the Centers for Disease Control and Prevention (CDC). In 2015 alone, 33,000 people died from opioid overdoses – more than guns, car crashes and HIV/AIDS ever killed in one year in the U.S.
Defendants include Purdue Pharma L.P.; Purdue Pharma, Inc.; The Purdue Frederick Company, Inc.; Teva Pharmaceutical Industries, LTD.; Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutical Inc. n/k/a Janssen Pharmaceuticals, Inc.; Noramco, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Allergan PLC f/k/a Actavis PLS; Watson Pharmaceuticals, Inc. n/k/a Actavis, Inc.; Watson Laboratories, Inc.; Actavis, LLC; Actavis Pharm a, Inc. f/k/a Watson Pharma, Inc.; Mallinckrodt plc; Mallinckrodt LLC; McKesson Corporation; Cardinal Health, Inc.; and AmerisourceBergen Drug Corporation.
The complaint is filed in the U.S. District Court for the Northern District of Alabama.